ArticleNature medicine2025
Global burden of chikungunya virus infections and the potential benefit of vaccination campaigns.
Article in Nature medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 54 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Maternal Chikungunya virus infection and pregnancy outcomes: a global systematic review and meta-analysis of vertical transmission dynamics and associated morbidity.Emerging microbes & infections · 2026Pooled it
- A bibliometric analysis of vaccine research on Chikungunya virus: contributors, trends, and emerging frontiers.Frontiers in immunology · 2025Pooled it
- Epitope Tagging and Coimmunoprecipitation to Identify Viral Protein Interactors.Methods in molecular biology (Clifton, N.J.) · 2027Article
- Naked-Eye Visual Loop-Mediated Isothermal Amplification Method for the Rapid Detection of Chikungunya Virus.Methods in molecular biology (Clifton, N.J.) · 2027Article
- Optimized Amplicon Strategy for Long-Read Sequencing of the Chikungunya Virus Genome.Methods in molecular biology (Clifton, N.J.) · 2027Article
- An ECSA-lineage chikungunya outbreak in Foshan, China: age-stratified clinical and virological profiles.Emerging microbes & infections · 2026Article
- Glutamine antagonist DON attenuates chikungunya virus-induced myositis by suppressing inflammatory activation in a murine model.Emerging microbes & infections · 2026Article
- A machine learning approach for differential classification of chikungunya virus: an explainable AI study based on surveillance data.Infection · 2026Article
- Development of Covalent Inhibitors of Chikungunya Virus nsP2 Cysteine Protease Enabled by Direct-to-Biology Synthesis and Screening.Journal of medicinal chemistry · 2026Article
- Development of a potential vaccine against dengue and chikungunya virus co-infection using immunoinformatics and structural evaluation.Journal, genetic engineering & biotechnology · 2026Article
- Detection and genomic characterization of a travel-associated ECSA lineage chikungunya virus infection in Mexico.ASM case reports · 2026Article
- Chikungunya waves in 2025 signal risk of endemicity in China.PLoS neglected tropical diseases · 2026Article
- Autoantibodies neutralizing type I interferons underlie a third of cases of Chikungunya virus encephalitis or myelitis.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- ENSO Impact on Global Chikungunya Virus Transmission, 2008-2024: A Multi-Country Distributed-Lag Time-Series Analysis.Viruses · 2026Article
- Vector competence acrossJournal of virology · 2026Review
- Chikungunya Vaccines in Travel Medicine: From Regulatory Approval to Real-World Challenges.Tropical medicine and infectious disease · 2026Review
- Acute-phase clinical profile and quality of life in patients with chikungunya during the 2025 outbreak in Bangladesh: A facility-based cross-sectional study.PLoS neglected tropical diseases · 2026Article
- Epidemic features and potential impact of vaccine campaigns on the 2025 chikungunya outbreak in southern China: a mathematical modelling study.New microbes and new infections · 2026Article
- Alphavirus replicase and regulatory RNA elements in host interactions and viral vector engineering.Journal of virology · 2026Review
- Molecular Evolution of the Chikungunya VirusViruses · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
16 authors.
Funding
Abstract
The first vaccine against chikungunya virus (CHIKV) has now been licensed; however, due to a limited knowledge of the underlying global burden, its potential to reduce disease burden remains unknown. We used data from seroprevalence studies, observed cases and mosquito distributions to quantify the underlying CHIKV burden in 180 countries and territories, and we explored the potential impact of vaccination campaigns. We estimate that 104 countries have experienced CHIKV transmission, covering 2.8 billion people, and that, in epidemic settings, the mean duration between outbreaks is 6.2 years, with 8.4% of the susceptible population infected per outbreak. Globally, there are 35 million annual infections, mainly in Southeast Asia, Africa and the Americas. Assuming a vaccine efficacy against disease of 70% and a protection against infection of 40%, vaccinating 50% of individuals over 12 years of age in places and times where the virus circulates would avert 4,436 infections, 0.34 deaths and 17 disability-adjusted life years per 100,000 doses used. These findings highlight the global burden of chikungunya and the potential of CHIKV vaccination campaigns.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.